Physician profile
Heidi Scronce
NPI 1447948716
$2,387.78
in general payments reported to CMS, 2019-2025
22 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 90% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $159 · 2024: $987 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.30 | 2023-2025 | |
| Novo Nordisk INC | $504.86 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $440.14 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.88 | 2025 | Caplyta |
| Pfizer INC. | $112.75 | 2023-2025 | |
| Amgen INC. | $91.40 | 2023-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.11 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $59.87 | 2024-2025 | Airsupra |
| Aimmune Therapeutics, INC. | $57.19 | 2024-2025 | Zenpep |
| Amneal Pharmaceuticals LLC | $56.87 | 2024-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $44.43 | 2025 | |
| Medtronic, INC. | $31.70 | 2023-2024 | Intellis Adaptivestim |
| Dexcom, INC. | $28.89 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $25.46 | 2025 | Nexplanon |
| Astellas Pharma US INC | $21.76 | 2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.06 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.57 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $16.78 | 2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $15.65 | 2025 | Capvaxive, Gardasil 9 |
| Insulet Corporation | $15.17 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $13.86 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $12.08 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Scronce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.